Subscribe
shutterstock_1755486332_anton_medvedev
Anton_Medvedev / Shutterstock.com
10 August 2021EuropeSophie Topham

UK experimental use exemptions: Part 4—the SPC manufacturing and stockpiling waiver

In the final article of a four-part series, Sophie Topham of Marks & Clerk discusses the supplementary protection certificate manufacturing waiver

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Generics
UK experimental use exemptions: Part 3—the expanded exemption
5 August 2021   In the third article of a four-part series on experimental use exemptions from infringement in the UK, Sophie Topham of Marks & Clerk considers the expansion of the original exemption.
Generics
UK experimental use exemptions: Part 2—the Bolar exemption
22 July 2021   In the second of a four-part series, Sophie Topham of Marks & Clerk explains the rules around the exemption for studies, tests, and trials required for generic and biosimilar medicines.


Editor's picks

LSPN: In-house ‘chess game’ is the same, but the rules have changed
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025

Editor's picks

Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025

More on this story

Generics
UK experimental use exemptions: Part 3—the expanded exemption
5 August 2021   In the third article of a four-part series on experimental use exemptions from infringement in the UK, Sophie Topham of Marks & Clerk considers the expansion of the original exemption.
Generics
UK experimental use exemptions: Part 2—the Bolar exemption
22 July 2021   In the second of a four-part series, Sophie Topham of Marks & Clerk explains the rules around the exemption for studies, tests, and trials required for generic and biosimilar medicines.

More on this story

Generics
UK experimental use exemptions: Part 3—the expanded exemption
5 August 2021   In the third article of a four-part series on experimental use exemptions from infringement in the UK, Sophie Topham of Marks & Clerk considers the expansion of the original exemption.
Generics
UK experimental use exemptions: Part 2—the Bolar exemption
22 July 2021   In the second of a four-part series, Sophie Topham of Marks & Clerk explains the rules around the exemption for studies, tests, and trials required for generic and biosimilar medicines.

More features

Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
'Nothing can stand in the way of our work': Ukraine resumes IP system
Taylor Wessing expands in Europe with Paris team
Foley adds five-partner team from Perkins Coie and K&L Gates
UPC orders 17-country ban on EOFlow's pumps in Insulet feud
Biotech and healthcare expert returns to Latham & Watkins
AstraZeneca to appeal invalidated diabetes patent in generics dispute